welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Thetis Pharmaceuticals to Present at the World Orphan Drug Congress on TP-252, an Investigational Drug for Familial Adenomatous Polyposis
Thetis Pharmaceuticals LLC (“Thetis”), a privately-held biopharmaceutical company, today announced that Frank C. Sciavolino, Ph.D., Chief Scientific Officer, will present an overview of TP-252, the Company’s investigational drug candidate for the treatment of familial adenomatous polyposis (FAP) at the 2016 World Orphan Drug Congress USA. The presentation will take place at the Washington Hilton in Washington, D.C. at 3 pm (EDT) on April 21, 2016.

expertly curated content related to this topic
-
StephanieI was diagnosed with Familial Adenomatou...
-
Sue Clark, MDSue Clark trained in medicine at Cambrid...
-
University of California, San Francisco Medical CenterPatient Resources: Center...
-
Travis H. BrayTravis Bray is the Founder and Executive...
-
Understanding Health InsuranceHealth insurance is a way to pay for hea...
-
Miguel A. Rodriguez-Bigas, MDProfessor, Department of Surgical Oncolo...